Navigation Links
Lilly Declares Third-Quarter Dividend
Date:6/22/2009

INDIANAPOLIS, June 22 /PRNewswire-FirstCall/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the third quarter of 2009 of $0.49 a share on outstanding common stock. This is the same dividend as was paid in the first and second quarters and maintains the annual indicated dividend rate for 2009 of $1.96 per share.

The dividend is payable September 10, 2009, to shareholders of record at the close of business on August 15, 2009.

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. F-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimers Disease Market
2. Eli Lilly and Company Announces New Drug Discovery Initiative
3. NAACP & Nine Class Reps File Motion for Class Certification Against Eli Lilly in Pervasive Discrimination Case
4. ICON Selected to Manage Lilly Clinical Trial Site Set Up and Monitoring in Europe
5. Bart Peterson to Join Lilly Leadership Team
6. Lilly Resubmits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
7. Amgens Denosumab and Eli Lillys Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
8. Covance Recognized for Outstanding Customer Service by Eli Lilly and Company
9. Lilly and Medtronic Form Alliance to Provide Solutions for Diabetes Management
10. Lilly to Celebrate Second Annual Global Day of Service May 20
11. Lilly Chairman & CEO Lechleiter Says Innovation Is Vital-But-Missing Plank in Health Reform Debate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... CA (PRWEB) , ... February 27, 2017 , ... ... muscle mass and overall body strength, which often leads to a host of ... Journal of the American Geriatrics Society discovered that good overall muscle ...
(Date:2/27/2017)... ... 27, 2017 , ... Much attention has been paid to the problem of ... opioid painkillers has fallen short. From 1999 until 2010, fatal overdoses from prescription pain ... overdoses in male populations.(1) , The proportion of women using illicit drugs is also ...
(Date:2/27/2017)... ... February 27, 2017 , ... ... on laser diffraction analysis as a tool to characterize particle size distributions in ... to obtain improved results and novel scientific findings. It describes methods of optimized ...
(Date:2/27/2017)... ... 27, 2017 , ... Sunshine Coast Health Centre (SCHC), one ... at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of a registered ... Centre's commitment to innovation in drug rehab and alcohol treatment strategies beyond a ...
(Date:2/26/2017)... ... ... The February 13, 2017, assassination of Kim Jong-nam, the half brother of ... deadly use of chemical weapons. Many questions exist about the effect that nerve agents ... lethal. , Jay Jagannathan, M.D., of Michigan-based Jagannathan Neurosurgical Institute, and one of the ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... -- International Biophysics Corporation, a global medical device manufacturer based in ... revenue growth in 2016 when compared to the previous year ... was fueled by its AffloVest® sales in the ... its global sales of surgical product lines. Said ... our 25 th year in delivering high-quality, innovative medical ...
(Date:2/27/2017)... Calif. , Feb. 27, 2017   Vitasome ... line of nutritional supplements using its groundbreaking new liposome ... 90 percent of potency through digestion per Physician,s ... supplements solve the problem of nutritional waste and are ... degradation during digestive processes Improve bioavailability ...
(Date:2/27/2017)... Feb. 27, 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... development company focused on tissue protection, repair and ... GtreeBNT Co., Ltd., received a positive response from ... trial design for RGN-137 to treat epidermolysis bullosa ... that incorporates Thymosin beta 4 ("Tß4") as the ...
Breaking Medicine Technology: